Novartis is preparing to present the trial findings to regulatory bodies in 2025. Credit: Novartis AG. Novartis has reported positive topline outcomes from the Phase III STEER trial of an ...

Sensorion has completed subject enrolment in the first cohort of Phase I/II Audiogene trial of gene therapy injection, SENS-501.

China NMPA's CDE has approved Alphamab Oncology’s IND for the multicentre Phase I/II JSKN033-102 trial of JSKN033.

XBiotech has said it will investigate the results of its rheumatoid arthritis trial after finding irregularities in its Phase II trial.

APAC was followed by North America and then Europe for percentage of clinical trials in Parkinson’s disease. Credit: AtlasStudio / Shutterstock. The Asia-Pacific (APAC) region is leading in the ...

The Phase III trial is set to use growth outcomes as its primary endpoint in the 52-week trial of JR-142, a long-acting growth hormone.

RAG-17 is tailored for the SOD1 gene suppression in individuals with ALS having pathogenic mutations. Credit: CC7/Shutterstock. Ractigen Therapeutics has dosed the first subject in the randomised ...

Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma delta CAR T-cell therapy for treating ccRCC.

AI continued to be shown as an invaluable tool with the potential to accelerate clinical trials and improve patient care.

Precision has gained the approval of its CTA in Hong Kong to study PBGENE-HBV in the Phase I trial for curing chronic hepatitis B.

Despite hitting its primary endpoints, the Novo Nordisk REDEFINE 1 Phase III trial saw patients achieving a weight loss of 22.7% after 68 weeks on CariSema. Credit: Getty Images / Bloomberg Danish ...

Zura Bio has initiated the Phase II TibuSURE trial to assess tibulizumab, in treating systemic sclerosis (SSc) in adult patients.